MedTrace Logo

A Phase 2 Study of BNC210 for the Acute Treatment of Social Anxiety Disorder

NCT05193409 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 151

Last updated 2025-03-18

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the effects of an acute dose of BNC210 compared to placebo on reducing anxiety provoked by a speaking challenge and measured using the Subjective Units of Distress Scale (SUDS) in patients with Social Anxiety Disorder (SAD).

Conditions

Interventions

DRUG

225 mg BNC210

225 mg BNC210

DRUG

675 mg BNC210

675 mg BNC210

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Bionomics Limited

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-02
Primary Completion
2022-10-10
Completion
2022-10-17
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05193409 on ClinicalTrials.gov